Abstract:Introduction: In the present study we evaluated the features of different recombinant forms of Zika virus (ZIKV) proteins produced in either bacterial (Eschericha coli) or insect cells (Drosophila melanogaster). The ZIKV-envelope glycoprotein (EZIKV) is responsible for virus entry into host cells, is the main target of neutralizing antibodies and has been used as a target antigen either for serological tests or for the development of subunit vaccines. The EZIKV is composed of three structural and functional domains (EDI, EDII, and EDIII), which share extensive sequence conservation with the corresponding counterparts expressed by other flaviviruses, particularly the different dengue virus (DENV) subtypes. Methods: In this study, we carried out a systematic comparison of the antigenicity and immunogenicity of recombinant EZIKV, EDI/IIZIKV and EDIIIZIKV produced in E. coli BL21 and Drosophila S2 cells. For the antigenicity analysis we collected 88 serum samples from ZIKV-infected participants and 57 serum samples from DENV-infected. For immunogenicity, C57BL/6 mice were immunized with two doses of EZIKV, EDI/IIZIKV and EDIIIZIKV produced in E. coli BL21 and Drosophila S2 cells to evaluate humoral and cellular immune response. In addition, AG129 mice were immunized with EZIKV and then challenge with ZIKV. Results: Testing of samples collected from ZIKV-infected and DENV-infected participants demonstrated that the EZIKV and EDIIIZIKV produced in BL21 cells presented better sensitivity and specificity compared to proteins produced in S2 cells. In vivo analyses were carried out with C57BL/6 mice and the results indicated that, despite similar immunogenicity, antigens produced in S2 cells, particularly EZIKV and EDIIIZIKV, induced higher ZIKV-neutralizing antibody levels in vaccinated mice. In addition, immunization with EZIKV expressed in S2 cells delayed the onset of symptoms and increased survival rates in immunocompromised mice. All recombinant antigens, either produced in bacteria or insect cells, induced antigen-specific CD4+ and CD8+ T cell responses. Conclusion: In conclusion, the present study highlights the differences in antigenicity and immunogenicity of recombinant ZIKV antigens produced in two heterologous protein expression systems.

[Preparation of monoclonal antibodies against the envelope protein extracellular domain of Zika virus in mice]

[Preparation of a Monoclonal Antibody Against Polyhedrin of Ectropis Obliqua Nucleopolyhedrovirus].

Characterization of Two Highly Specific Monoclonal Antibodies Targeting the Glycan Loop of the Zika Virus Envelope Protein

Critical Neutralizing Fragment Of Zika Virus Ediii Elicits Cross-Neutralization And Protection Against Divergent Zika Viruses

Baculovirus Surface Display of Zika Virus Envelope Protein Protects against Virus Challenge in Mouse Model

A Single Injection of Human Neutralizing Antibody Protects Against Zika Virus Infection and Microcephaly in Developing Mouse Embryos.

Delineating Antibody Recognition Against Zika Virus During Natural Infection.

Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region

An inactivated recombinant rabies virus displaying the Zika virus prM-E induces protective immunity against both pathogens

Rational design and production of a chimeric antigen targeting Zika virus that induces neutralizing antibodies in mice

Neutralization of Zika Virus by Germline-Like Human Monoclonal Antibodies Targeting Cryptic Epitopes on Envelope Domain III

Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection

Japanese encephalitis virus E protein domain III immunization mediates cross-protection against Zika virus in mice via antibodies and CD8 + T cells

Molecular Determinants of Human Neutralizing Antibodies Isolated from a Patient Infected with Zika Virus.

Diagnostic and vaccine potential of Zika virus envelope protein (E) derivates produced in bacterial and insect cells

Development of a Potent and Protective Germline-Like Antibody Lineage Against Zika Virus in a Convalescent Human

Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40

Preparation and Characterization of Monoclonal Antibody Against M Protein of Dengue Virus Serotype 2

Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes

Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice

A Small Antigenic Determinant of the Chikungunya Virus E2 Protein Is Sufficient to Induce Neutralizing Antibodies which Are Partially Protective in Mice